17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
Key Takeaways
- State medical cannabis programs authorize possession under state law but do not make any cannabis product FDA-approved, and APRNs certify qualifying conditions rather than writing prescriptions.
- Effective April 28, 2026, marijuana in an FDA-approved drug product and marijuana subject to a qualifying state medical marijuana license moved to Schedule III, while all other marijuana remains Schedule I.
- Cannabis use in adolescence is associated with a dose-dependent increase in risk of psychotic disorders, with the largest associations for daily high-potency use.
- Prenatal cannabis exposure is associated with lower birth weight and neurodevelopmental concerns, and THC concentrates in breast milk, so ACOG advises against use in pregnancy and lactation.
- Cannabis roughly doubles motor vehicle crash risk and combines more than additively with alcohol, and there is no blood THC threshold that reliably defines impairment.
17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
Quick Answer: State medical cannabis programs let an authorized clinician certify a qualifying condition; they do not create a prescription and do not make any product FDA-approved. Federal status changed on April 28, 2026, when marijuana in an FDA-approved drug product and marijuana subject to a qualifying state medical marijuana license moved to Schedule III, while all other marijuana — including adult-use and bulk marijuana — remains Schedule I. Cannabis in adolescence carries a dose-dependent association with psychotic disorders. ACOG advises against use in pregnancy and lactation. Cannabis roughly doubles crash risk and there is no reliable blood THC impairment threshold.
1. Certification Is Not Prescription
| Feature | Prescription drug | State medical cannabis |
|---|---|---|
| Federal approval | FDA-reviewed for safety and efficacy | None for whole-plant products |
| Clinician action | Writes a prescription | Certifies a qualifying condition under state law |
| Product standardization | Strength, purity and bioequivalence regulated | Varies by state program and dispensary |
| Dose | Specified | Patient-selected in practice |
| Pharmacist role | Dispenses with counseling and interaction checking | Dispensary staff are typically not licensed pharmacists |
APRN eligibility to certify varies widely by state — some programs allow APRNs to certify independently, some require physician involvement, and some exclude APRNs entirely. Verify current state law before certifying; this is a scope-of-practice question, not a clinical one.
2. Where the Evidence Is Strongest and Weakest
| Indication | Evidence position |
|---|---|
| Chemotherapy-induced nausea and vomiting | Supported (FDA-approved synthetic agents exist) |
| Chronic pain, especially neuropathic | Modest benefit in meta-analysis; effect sizes smaller than patients expect |
| Multiple sclerosis spasticity | Supported for nabiximols where available |
| Rare epilepsy syndromes | Supported for purified cannabidiol (Epidiolex) |
| PTSD, anxiety, depression, sleep | Weak or absent; these are among the most common qualifying conditions and have the least support |
| Opioid sparing | Population-level claims have not held up in longitudinal individual-level studies |
The honest counseling statement: "For a few conditions there is real evidence. For the conditions most people are certified for, the evidence is thin, and there is a real risk of developing a cannabis use disorder — especially if you use daily or use concentrates."
3. Adolescent Risk
- Psychosis: cannabis use is associated with increased risk of psychotic disorders in a dose-dependent pattern, with the strongest associations for daily use of high-potency products. Risk is concentrated in people with genetic vulnerability and early onset. The association does not establish causation in any individual case, but it is strong enough to warrant explicit counseling for adolescents and for anyone with a family history of psychosis.
- Cognition: heaviest effects on attention, learning and processing speed during active use and early abstinence; substantial recovery with sustained abstinence, though debate continues about residual effects with very early onset.
- Education and employment: dose-dependent associations with school dropout and reduced attainment.
- Route matters: dabbing concentrates and using high-concentration vape cartridges produce far higher exposure than flower and are increasingly the adolescent norm.
4. Pregnancy and Lactation
- ACOG advises against cannabis use in pregnancy and lactation, and recommends against "medical" cannabis in pregnancy in favor of alternative therapies with better safety data.
- Prenatal exposure is associated with lower birth weight and neurodevelopmental concerns.
- THC concentrates in breast milk and is detectable for days to weeks; the infant's brain is undergoing rapid development.
- Cannabis is commonly used for hyperemesis gravidarum, creating a diagnostic trap: persistent vomiting in a pregnant daily cannabis user may be cannabinoid hyperemesis syndrome, not hyperemesis gravidarum.
- Counsel without threat. In many jurisdictions a positive toxicology result triggers a child-welfare report, and patients know it — which is exactly why disclosure requires a trust-first approach and clear information about what the APRN is and is not required to report.
5. Driving
- Cannabis approximately doubles motor vehicle crash risk.
- Combining cannabis with alcohol produces impairment greater than either alone.
- Blood THC concentration correlates poorly with impairment, particularly in chronic users who maintain measurable levels while not acutely impaired. Per se blood THC limits in some states are therefore scientifically contested.
- Practical counseling: impairment after inhaled use persists well beyond the subjective "high," and after edibles it can last much longer. The defensible advice is not to drive for several hours after inhaled use and considerably longer after oral use, and never to combine with alcohol.
6. A Compact Patient Education Script
- Legal status: "State law and federal law are not the same, and as of 2026 only part of the federal picture changed. Employment, firearms, housing and immigration consequences can still follow."
- Potency: "What is sold now is several times stronger than what existed when most of the research was done. Concentrates are stronger still."
- Route: "Edibles take up to two hours. Most bad reactions come from eating more during that wait."
- Who should be most careful: "People under 25, people with a family history of psychosis, people who are pregnant or breastfeeding, and anyone using daily."
- Driving: "There is no reliable number for cannabis like there is for alcohol. Give it hours, and never mix it with drinking."
- Teach-back: ask the patient to state, in their own words, the two things they will change.
A patient asks whether marijuana is still a Schedule I drug under federal law. What is the accurate response as of September 2026?
A 16-year-old with a family history of schizophrenia dabs cannabis concentrate daily. Which counseling point is best supported by the evidence?
A pregnant patient at 9 weeks reports using cannabis edibles daily for nausea and says a dispensary employee told her it is "natural and safe in pregnancy." What should the APRN counsel?